script.reportAU
Infectious disease

Bictegravir + emtricitabine + tenofovir alafenamide

Brand: Biktarvy®

PBAC's latest decision on Bictegravir + emtricitabine + tenofovir alafenamide: Deferred (2018). Considered for Treatment of human immunodeficiency virus (HIV-1) infection in treatment-naïve and virologically suppressed patients.

PBAC outcome
Deferred
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2018
Submissions
1
2018 → 2018

Eligible population

Adults with HIV-1 infection, including treatment-naïve patients and virologically suppressed treatment-experienced patients.

Therapy area
Infectious disease
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
Surrogate
Pivotal trial size
600 patients
Key trials
GS-US-380-1490, GS-US-380-1878, GS-US-380-1489, GS-US-380-1844
Comparator
DESCOVY® (emtricitabine + tenofovir alafenamide) plus dolutegravir (primary); GENVOYA® and ODEFSEY® (secondary); lowest-priced alternative FDC triple-therapy (TDF-based: STRIBILD®, EVIPLERA®)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. PBAC considered cost-effectiveness would be acceptable if BFTAF were cost-minimised against the lowest priced alternative FDC triple-therapy for HIV treatment.

Similar precedents

Open on full dashboard →